AKBA (Akebia Therapeutics) Cyclically Adjusted FCF per Share: $-0.88 (As of Mar. 2026)


AKBA Akebia Therapeutics Inc AKBA
47 GF Score
Price $1.40
GF Value $1.29
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Cyclically Adjusted FCF per Share?

Akebia Therapeutics AKBA -2.78% 47 Cyclically Adjusted FCF per Share is $-0.88 as of Mar. 2026. GuruFocus rates AKBA with a GF Score™ of 47/100 and a GF Value™ of $1.29 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Akebia Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.080. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-0.88 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 20.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Akebia Therapeutics was 20.10% per year. The lowest was 20.10% per year. And the median was 20.10% per year.

As of today (2026-07-12), Akebia Therapeutics's current stock price is $1.40. Akebia Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-0.88. Akebia Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Akebia Therapeutics  (NAS:AKBA) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Akebia Therapeutics Cyclically Adjusted FCF per Share Related Terms


Akebia Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Akebia Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Akebia Therapeutics Cyclically Adjusted FCF per Share Chart

Akebia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -1.55 -1.50 -1.05 -0.79

Akebia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.01 -0.95 -0.91 -0.79 -0.88

AKBA vs TKNO, ORGO, SIGA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Akebia Therapeutics Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Akebia Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


AKBA
47GF Score
Akebia Therapeutics Inc AKBA
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Akebia Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Akebia Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.08/330.2130*330.2130
=-0.080

Current CPI (Mar. 2026) = 330.2130.

Akebia Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.746 241.018 -1.022
201609 -0.778 241.428 -1.064
201612 2.498 241.432 3.417
201703 -0.257 243.801 -0.348
201706 0.593 244.955 0.799
201709 -1.176 246.819 -1.573
201712 -0.355 246.524 -0.476
201803 -0.424 249.554 -0.561
201806 0.155 251.989 0.203
201809 -0.224 252.439 -0.293
201812 -1.072 251.233 -1.409
201903 -1.195 254.202 -1.552
201906 -0.341 256.143 -0.440
201909 0.071 256.759 0.091
201912 -0.774 256.974 -0.995
202003 -0.698 258.115 -0.893
202006 0.272 257.797 0.348
202009 -0.190 260.280 -0.241
202012 -0.212 260.474 -0.269
202103 -0.460 264.877 -0.573
202106 -0.391 271.696 -0.475
202109 -0.324 274.310 -0.390
202112 -0.360 278.802 -0.426
202203 -0.121 287.504 -0.139
202206 -0.161 296.311 -0.179
202209 0.184 296.808 0.205
202212 -0.297 296.797 -0.330
202303 -0.095 301.836 -0.104
202306 0.019 305.109 0.021
202309 -0.038 307.789 -0.041
202312 -0.012 306.746 -0.013
202403 -0.095 312.332 -0.100
202406 -0.048 314.175 -0.050
202409 -0.032 315.301 -0.034
202412 -0.020 315.605 -0.021
202503 -0.056 319.799 -0.058
202506 0.082 322.561 0.084
202509 0.102 324.800 0.104
202512 0.088 324.054 0.090
202603 -0.080 330.213 -0.080

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-0.88 mean?
Akebia Therapeutics (AKBA) has a Cyclically Adjusted FCF per Share of $-0.88 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors.
Is Akebia Therapeutics' Cyclically Adjusted FCF per Share too high?
Akebia Therapeutics' current Cyclically Adjusted FCF per Share is $-0.88. Overall, Akebia Therapeutics has a GF Score™ of 47/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Akebia Therapeutics' Cyclically Adjusted FCF per Share compare to TKNO and ORGO?
Akebia Therapeutics' Cyclically Adjusted FCF per Share of $-0.88 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Akebia Therapeutics and its competitors. Akebia Therapeutics's current Cyclically Adjusted FCF per Share is $-0.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akebia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Akebia Therapeutics (AKBA) is currently considered Fairly Valued. The stock's GF Value™ is $1.29, compared to a current price of $1.40 — trading 8.5% above its estimated fair value. The current Cyclically Adjusted FCF per Share is $-0.88. Akebia Therapeutics' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Akebia Therapeutics (AKBA), the current Cyclically Adjusted FCF per Share is $-0.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Akebia Therapeutics (AKBA) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of $1.40 is trading 8.5% above its estimated GF Value™ of $1.29. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for AKBA:

  • Cyclically Adjusted FCF per Share: $-0.88
  • GF Value™: $1.29 vs. price of $1.40 (8.5% above fair value)
  • GF Score™: 47/100 with 5 warning signs

No single metric tells the full story. See the AKBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akebia Therapeutics Business Description

Other Exchanges AX9:Germany
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
47GF Score

Get the complete analysis for AKBA

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.40
Price
$1.29
GF Value